(IMAGE)

City University of Hong Kong

Caption

Under short-period irradiation with low intensity of red light, without the need of any external catalyst, phorbiplatin is reduced to oxaliplatin, a first-line clinical antineoplastic, as well as pyropheophorbide a (PPA), a photoactivation ligand. Both substances are effective in killing tumor cells.

Credit

Wang et al., Phorbiplatin, a Highly Potent Pt(IV) Antitumor Prodrug That Can Be Controllably Activated by Red Light, Chem (2019), https://doi.org/10.1016/j.chempr.2019.08.021

Usage Restrictions

The image can only be used with appropriate caption and credit

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.